Liquidia Corporation - LQDA STOCK NEWS

Liquidia Corporation (NASDAQ: LQDA) announced the presentation of data on YUTREPIA™ (treprostinil) inhalation powder at the ATS International Conference 2022 in San Francisco. The research, focusing on safety and tolerability in treating pulmonary arterial hypertension (PAH), was presented by Dr. Nicholas P. Hill from Tufts Medical Center. YUTREPIA, an investigational drug, has FDA tentative approval aimed at improving exercise ability in adults with NYHA Functional Class II-III symptoms. The company emphasizes its proprietary PRINT® technology used in the drug's development.

Liquidia Corporation (LQDA) reported its Q1 2022 financial results, showing revenue growth to $3.5 million, up from $3.1 million year-over-year. The company secured $53.7 million from a stock offering and increased its credit facility, enhancing its financial position for the anticipated launch of YUTREPIA™. Key corporate actions include advancing its Hatch-Waxman litigation for YUTREPIA approval and bolstering the utilization of Treprostinil Injection amid payer mandates. However, the net loss widened to $15.9 million, compared to $9.2 million in Q1 2021, reflecting higher administrative expenses.

Liquidia Corporation (NASDAQ: LQDA) will report its first quarter 2022 financial results on May 12, 2022. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. Investors can access the call by dialing 1-877-707-8711 domestically or 1-857-270-6219 internationally, using conference code 4798065. The webcast will be archived for 30 days. Liquidia focuses on pulmonary hypertension treatments using its PRINT® Technology and has developed YUTREPIA™ for pulmonary arterial hypertension.

Liquidia Corporation (NASDAQ: LQDA) announced the grant of stock options for 35,700 shares to newly hired non-executive employees under its 2022 Inducement Plan. Each stock option, granted as a material inducement for employment acceptance, has an exercise price of $5.63 per share, reflecting the closing price on April 22, 2022. These options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) aimed at attracting talent to support Liquidia's growth in pulmonary hypertension treatments.

Liquidia Corporation (NASDAQ: LQDA) announced that Dr. Sandeep Sahay will present clinical data on YUTREPIA™ (treprostinil) inhalation powder at the 42nd Annual Meeting of the International Society for Heart and Lung Transplant in Boston. The presentation titled 'Risk Assessment in Pulmonary Arterial Hypertension (PAH): Insights from the INSPIRE Study' will occur on April 27, 2022. YUTREPIA, a treatment for PAH, received tentative FDA approval on November 5, 2021, aimed at improving exercise ability in adults with specific symptoms.

Liquidia Corporation (NASDAQ: LQDA) has successfully closed an underwritten public offering of 11,274,510 shares of common stock, raising approximately $57.5 million. The offering included the full exercise of an over-allotment option for an additional 1,470,588 shares at $5.10 per share. Proceeds will support the commercial development of YUTREPIA™ and ongoing clinical trials for various patient groups. BofA Securities led the offering, with Needham & Company and BTIG as co-managers.

Liquidia Corporation (NASDAQ: LQDA) announced the pricing of an underwritten public offering of 9,803,922 shares at $5.10 per share, totaling approximately $50.0 million in gross proceeds. The offering is set to close on April 18, 2022, subject to customary conditions. The underwriters have a 30-day option to purchase an additional 1,470,588 shares. This offering is conducted under Liquidia's previously filed shelf registration statement with the SEC. BofA Securities is the sole book-running manager for this offering.

Liquidia Corporation (NASDAQ: LQDA) announced the commencement of an underwritten public offering of its common stock, with all shares sold by the company. The underwriters may purchase an additional 15% of the shares within 30 days at the offering price. The offering relies on a previously filed shelf registration statement and is subject to market conditions. BofA Securities is the sole book-running manager. The net proceeds will be used for corporate purposes, although specific details were not provided. Completion of the offering is uncertain.

Liquidia Corporation (NASDAQ: LQDA) announced the grant of a stock option for 2,000 shares to a newly hired non-executive employee as part of its 2022 Inducement Plan. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and serves as an employment incentive. The option is exercisable at $6.94 per share, the closing price on March 21, 2022, and has a ten-year term with a vesting schedule over four years.

Liquidia focuses on developing treatments for pulmonary hypertension using its PRINT® Technology and has launched YUTREPIA™ for pulmonary arterial hypertension.